H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company’s shares opened today at $0.83. Arce covers the Healthcare sector, focusing on ...

On Wednesday, H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock rating from Buy to Neutral. The downgrade has intensified ...

HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. Get Immunocore ...

NEW YORK--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years ...

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings NEW YORK, January 27, 2025--(BUSINESS WIRE)--H.C.

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), with a price target of $3.50. The company’s shares ...

On Tuesday, H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a price target of $180.00. According to InvestingPro data, this ...

NioCorp Developments Ltd. (NASDAQ:NB – Free Report) – Investment analysts at HC Wainwright increased their FY2025 earnings estimates for shares of NioCorp Developments in a research note ...

On Monday, H.C. Wainwright adjusted its outlook on Eton Pharmaceuticals (NASDAQ:ETON), raising the price target to $17.00 from the previous $15.00 while maintaining a Buy rating on the company's ...